Hanall BioPharma announced on the 29th that it recorded an operating profit of KRW 5.6 billion in the preliminary consolidated results for the second quarter of 2026, a 388.5% surge compared to the same period last year.

■ Q2 Performance Summary Revenue reached KRW 44.276 billion, up 10.6% from the previous quarter (KRW 40.031 billion) and up 8.8% from the same period last year (KRW 40.682 billion). Operating profit stood at KRW 5.598 billion, representing increases of 567.4% from the previous quarter (KRW 0.839 billion) and 388.5% from the same period last year (KRW 1.146 billion), respectively.

■ H1 Cumulative Performance On a cumulative basis for the first half (January–June), the company achieved revenue of KRW 84.306 billion and operating profit of KRW 6.436 billion. In the same period last year, cumulative revenue was KRW 76.832 billion and cumulative operating profit was KRW 0.751 billion. The disclosure did not include the year-over-year change rates for cumulative revenue and operating profit.

■ Net Profit Turns to Loss Meanwhile, net profit, a key profitability indicator, recorded a loss. Profit from continuing operations before income tax for the second quarter posted a loss of KRW 21.5 billion, turning to a deficit compared to both the previous quarter (KRW 0.57 billion profit) and the same period last year (KRW 1.046 billion profit). Net profit for the period and net profit attributable to owners of the parent company also each recorded a loss of KRW 19.229 billion, turning to a deficit compared to both the previous quarter and the same period last year.

Hanall BioPharma stated that these results are preliminary consolidated figures prepared in accordance with the Korean International Financial Reporting Standards (K-IFRS), based on internal closing data prior to review by the external auditor, and may be subject to change depending on the audit results.